搜尋結果
Hims & Hers Down Sharply Again as Scrutiny Over Ozempic Knockoff Business Grows
The Wall Street Journal· 1 日前Shares of Hims & Hers, the telehealth company, are under pressure as scrutiny of its weight ...
InnovationRx: Oracle Debuts AI Tool To Cut Doctor’s Screen Time By 50%
Forbes· 3 日前The company says its new tool–which will automatically transcribe patient conversations and input them ...
Is Success Possible When Rivals Partner?
Forbes· 6 日前... pundits try to identify Donald Trump’s vice-presidential pick, one name leading the dark ...
Takeda To Keep Pushing for China Biotech Partnerships, CEO Says
Bloomberg· 3 日前Have a confidential tip for our reporters? Takeda Pharmaceutical Co. will keep up efforts to ...
Quantum Computing Takes Off With $55 Billion In Global Investments
Forbes· 2 日前The quantum market is already estimated to be worth more than $1 billion this year ...
Ozempic Maker Novo Nordisk Plans Another $4.1 Billion US Factory
Bloomberg· 4 日前Novo Nordisk A/S plans to invest $4.1 billion in another US factory, plowing more money into ...
23andHim: The Untold Story Of 23andMe’s Third Co-Founder
Forbes· 4 日前Valued at $6 billion at its peak, the company has been consistently trading under one dollar ...
Author Post: Hospital Consolidation Not the Main Culprit; Workforce Shortages Are
Forbes· 5 日前While it is undeniable that there has been significant consolidation among hospitals (1,887 ...
Council Post: Employee Spending Accounts: Understanding Employers' Options
Forbes· 4 日前Organizations face new challenges in supporting dispersed and diverse workforces in today’s ...
Walgreens Shares Crash 24%—On Track For Worst Day Since 1970s
Forbes· 2 日前Shares for Walgreens fell over 24% on Thursday, pacing the company’s worst loss since ... ...